Favorable safety profile seen for relapsed\/refractory large B-cell lymphoma patients monitored as outpatients or inpatients<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Oct. 7, 2024 (HealthDay News) — For patients with relapsed\/refractory large B-cell lymphoma (LBCL), the autologous, CD19-directed, 4-1BB chimeric antigen receptor T-cell product, lisocabtagene maraleucel (liso-cel), is safe for outpatients and inpatients and is efficacious, according to a study published online Sept. 30 in Blood Advances<\/em>.<\/p>\n Yuliya Linhares, M.D., from the Miami Cancer Institute, and colleagues examined outpatient safety and efficacy following liso-cel treatment at community sites in the United States among adults with relapsed\/refractory LBCL after two or more prior lines of therapy. Eighty-two patients received liso-cel (70 percent outpatient-monitored; 30 percent inpatient-monitored) and were followed for a median of 10.6 months.<\/p>\n The researchers found that grade 3 or higher cytokine release syndrome occurred in 0 and 0 percent of outpatients and inpatients, respectively; neurological events occurred in 12 and 4 percent; infections in 12 and 8 percent; and prolonged cytopenia in 33 and 32 percent. Twenty-five percent of outpatients were never hospitalized after infusion and 32 percent were hospitalized within 72 hours after the day of infusion; the median time to hospitalization was 5.0 days. After liso-cel, median initial hospitalization duration was 6.0 and 15.0 days for outpatients and inpatients, respectively. The objective response rate and complete response rate were 80 and 54 percent, respectively; the median duration of response was 14.75 months.<\/p>\n “These findings support liso-cel treatment at community medical centers using standard operating procedures and multidisciplinary teams with outpatient monitoring in appropriate patients,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Bristol Myers Squibb, which manufactures liso-cel and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n